摘要
利妥昔单抗(Rituximab,RTX)是用于治疗非霍奇金淋巴瘤的抗CD20人/鼠嵌合型单克隆抗体,也是一种有效治疗自身免疫性疾病的药物。其疗效确切,耐受性及安全性较好,已逐渐成为治疗肾小球肾炎的重要药物之一。文中主要对RTX在抗中性粒细胞胞浆抗体(antineutrophil cytoplasmic antibody,ANCA)相关小血管炎、狼疮性肾炎、混合性冷球蛋白血症、膜性肾病、微小病变肾病和局灶节段性肾小球硬化中的应用作一综述。
Rituximab（ RTX） is a monoclonal antibody to the CD20 antigen on B- cells that was initially designed and approved for the treatment of non-Hodgkin＇s B-cell lymphoma and has emerged as a potent immunosuppressant for many immune-mediated diseases. Given its efficacy,tolerability and safety profile in comparison to more conventional treatment regimens,RTX is rapidly emerging as a critical therapeutic modality for glomerular disease. The paper reviews the role of RTX in the treatment of ANCA-associated vasculitis,lupus nephritis,mixed cryoglobulinemia,membranous nephropathy,minimal change disease,and focal segmental glomerulosclerosis.
出处
《医学研究生学报》
CAS
北大核心
2015年第11期1204-1208,共5页
Journal of Medical Postgraduates
基金
国家自然科学基金(81270799)
